| Author | Coutinho, Julia Penna | |
| Author | Almela, Maria Jesús | |
| Author | Miguel-Blanco, Celia | |
| Author | Herreros, Esperanza | |
| Author | Sá, Paula M. | |
| Author | Boechat, Núbia | |
| Author | Krettli, Antoniana Ursine | |
| Access date | 2017-07-31T17:49:14Z | |
| Available date | 2017-07-31T17:49:14Z | |
| Document date | 2016 | |
| Citation | COUTINHO, Julia Penna et al. Transmission-Blocking Potential of MEFAS, a Hybrid Compound Derived from Artesunate and Mefloquine. Antimicrob Agents Chemother, v. 60, n. 5. p, 3145–3147, 2016 | pt_BR |
| ISSN | 0066-4804 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/20464 | |
| Language | eng | pt_BR |
| Publisher | American Society for Microbiology | pt_BR |
| Rights | restricted access | pt_BR |
| Subject in Portuguese | antimalíricos | pt_BR |
| Subject in Portuguese | Plasmodium falciparum | pt_BR |
| Title | Transmission-Blocking Potential of MEFAS, a Hybrid Compound Derived from Artesunate and Mefloquine | pt_BR |
| Type | Article | |
| DOI | 10.1128/AAC.02216-15 | |
| Abstract | Most antimalarial drugs target asexual parasites without reducing gametocyte formation or development. Drugs with dual roles, i.e., those that can target both asexual parasites and gametocytes, would improve the control of malaria. In the current study, MEFAS, a hybrid drug derived from mefloquine and artesunate that has been shown to be an active blood schizonticidal drug, was assessed to determine its ability to block the infectivity of Plasmodium falciparum gametocytes. MEFAS was 280 and 15 times more effective than mefloquine alone and artesunate alone, respectively. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Malária Experimental e Humana. Belo Horizonte, MG, Brazil/Universidade Federal de Minas Gerais. Programa de Medicina Molecular. Faculdade de Medicina. Belo Horizonte, MG, Brazil/Malaria Discovery Performance Unit. GlaxoSmithKline R&D. Madrid, Spain | pt_BR |
| Affilliation | Malaria Discovery Performance Unit. GlaxoSmithKline R&D. Madrid, Spain | pt_BR |
| Affilliation | Malaria Discovery Performance Unit. GlaxoSmithKline R&D. Madrid, Spain | pt_BR |
| Affilliation | Malaria Discovery Performance Unit. GlaxoSmithKline R&D. Madrid, Spain | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Farmanguinhos. Rio de Janeiro, RJ, Brazil | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Farmanguinhos. Rio de Janeiro, RJ, Brazil | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Malária Experimental e Humana. Belo Horizonte, MG, Brazil/Universidade Federal de Minas Gerais. Programa de Medicina Molecular. Faculdade de Medicina. Belo Horizonte, MG, Brazil | pt_BR |
| Subject | Antimalarial | pt_BR |
| Subject | Plasmodium falciparum | pt_BR |
| Embargo date | 2025-01-01 | |
